Susquehanna International Group
TCRR

Susquehanna International Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Susquehanna International Group’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,100
Closed -$56K – 14243
2022
Q3 		$56K Buy
31,100
+16,700
+116% +$48.4K ﹤0.01% 12127
2022
Q2 		$42K Buy
+14,400
New +$35.5K ﹤0.01% 12075
2022
Q1 		– Sell
-10,300
Closed -$48K – 14342
2021
Q4 		$48K Sell
10,300
-86,400
-89% -$540K ﹤0.01% 12578
2021
Q3 		$823K Sell
96,700
-8,500
-8% -$120K ﹤0.01% 8064
2021
Q2 		$1.73M Buy
105,200
+48,900
+87% +$988K ﹤0.01% 6272
2021
Q1 		$1.24M Sell
56,300
-9,900
-15% -$270K ﹤0.01% 7146
2020
Q4 		$2.05M Buy
66,200
+26,200
+66% +$662K ﹤0.01% 5046
2020
Q3 		$813K Buy
+40,000
New +$702K ﹤0.01% 6631
2020
Q2 		– Sell
-14,100
Closed -$109K – 11196
2020
Q1 		$109K Buy
+14,100
New +$173K ﹤0.01% 9262

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Susquehanna International Group's TCRR Position: Q1 2022 in Review

Susquehanna International Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 77,501 shares — an estimated $361K sold.

Susquehanna International Group first reported a position in TCRR in Q1 2020 and held it in 8 quarters. The position peaked at $1.28M in Q4 2020. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • Susquehanna International Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Susquehanna International Group sold 77,501 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $361K.
  • Susquehanna International Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 8 quarters.
  • Susquehanna International Group's TCR2 Therapeutics Inc. Common Stock position peaked at $1.28M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on Susquehanna International Group's 13F filing for Q1 2022, filed 16 May 2022.